<DOC>
	<DOCNO>NCT01515189</DOCNO>
	<brief_summary>The purpose study determine whether give Ipilimumab dose 10mg/kg extend life subject unresectable metastatic melanoma give Ipilimumab dose 3 mg/kg</brief_summary>
	<brief_title>Phase 3 Trial Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Unresectable Stage III Stage IV melanoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Brain metastasis symptoms require treatment History autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>